Two different sets of claims come with this product, and only one of them carries the disclaimer it needs. Here is every one, with what it rests on.
Written by the Nerve Recovery Max editorial team·Last updated October 11, 2026·How this page was checked
Nerve Recovery Max carries three structure-function claims on the front of the bottle — healthy nerve function, the neurological system, and blood flow and circulation — each with a dagger resolving to the FDA disclaimer on the back, which is the correct construction. The guarantee panel supplied with the product carries three different claims: support healthy nerve function, promote everyday comfort, and stay active and independent, and they carry no dagger where we were shown them. Of all six, the ones with anything behind them rest on two ingredients: alpha-lipoic acid at 400 mg, which NCCIH names as having weak evidence of a possible benefit for diabetic neuropathy, and benfotiamine at 150 mg, which is the monotherapy dose of the trial we opened. Blood flow and circulation is supported by nothing in this bottle. No trial exists on the combination, so no benefit can be quantified for the product as sold.
This is the first thing to notice about the marketing for this product, and it is easy to miss because the two documents arrive in the same envelope.
On the bottle, under the wordmark, three phrases with three small icons: healthy nerve function†, the neurological system† and blood flow & circulation†. Each carries a dagger. The dagger resolves, on the back of the same label, to the standard disclaimer: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” That is the correct construction, and a great many packs this desk has read get it wrong.
On the guarantee panel supplied with it, three different promises: Support Healthy Nerve Function. Give your nerves the nutrients they rely on every day. · Promote Everyday Comfort. Support healthy and comfortable hands and feet. · Stay Active and Independent. Support the mobility to keep doing what you love.
Those three carry no dagger and no disclaimer where we were shown them, and the third of them is not a structure-function claim at all. Stay active and independent is a claim about a life. Keep doing what you love is a claim about a life. Neither describes a structure or a function of the body, which is what the category of claim is named for.
We are not saying anyone broke a rule — we have seen one panel, not the page it sits on, and the disclaimer may well appear elsewhere on it. We are saying that the bottle is careful and the marketing is less careful, and that the gap between the two is where a buyer's expectations get set.
The bottle. Always. It is the thing that has to be right in a way a landing page does not, and on this product it is also the more conservative of the two.
Six of the ten ingredients could be drawn against a published figure. These are the bars underneath every benefit on this page.
A printed amount that reaches the figure its own research usedA printed amount that does notWhat the research, or the Daily Value, usedone linear scale per row — compare the fraction filled, not the length
Ten ingredients are printed on this panel, every one with its own amount. Six could be drawn here. The other four could not, and the reasons are the review.
Three are powders with no comparison we would publish. Ashwagandha root, broccoli leaf and turmeric root, 25 mg apiece. NCCIH records that some ashwagandha preparations may help insomnia and stress — nothing about nerves — and that we do not know enough to conclude turmeric is beneficial for any health purpose. On broccoli leaf powder we found no source we would cite at all.
And one cannot be drawn because the line cannot be right. Vitamin B6 is printed as 1.7 micrograms against a Daily Value the NIH gives as 1.7 milligrams, with 100%% claimed beside it. There is no honest bar to draw for a figure that is either right or a thousand-fold out.
Every bar here is a printed amount. Not one is a ceiling, an estimate or an inference — which is the whole difference between this panel and most of the shelf.
The best-supported of the three, and still not strong. It rests on alpha-lipoic acid at 400 mg against a studied 600, on benfotiamine at 150 mg against the trial's own monotherapy arm, and on B12 at 83% of a Daily Value where deficiency is a documented cause of numbness. It also rests on acetyl L-carnitine at a thirtieth of its threshold and three powders with no comparison.
The vaguest of the three and the hardest to attach to anything. No ingredient on this panel has a published trial for the neurological system as such. The trials that exist are for diabetic peripheral neuropathy specifically, in people who already have it. Lawful, daggered, and close to meaningless.
Supported by nothing in this bottle. None of the ten ingredients is a circulation agent at the amounts printed, and no source we opened connects any of them to blood flow at these doses. The alpha-lipoic acid trials measured symptom scores, not perfusion. We found nothing and we publish nothing.
The B vitamins are the only part of this that is checkable, and one of them is genuinely relevant: B12 deficiency causes numbness and tingling in the hands and feet, per the NIH. But “rely on every day” implies a deficiency you may not have, and the way to find out is a blood test rather than a bottle.
This is the claim closest to what the trials actually measured. SYDNEY 2's primary outcome was a Total Symptom Score, which is exactly this kind of comfort rather than a laboratory marker. Its dose was 600 mg; this label prints 400.
Nothing in the research behind this formula measured mobility, independence or activity. This is the claim that reaches furthest past the evidence, and it is the one aimed most precisely at the person most likely to buy.
It is worth writing the negatives down plainly, because the absence of a claim is harder to notice than its presence.
Nobody can tell you how often it works. No trial exists on this combination, so there is no response rate, no number needed to treat and no proportion of people who improved. Any percentage you are shown has been invented.
Nobody can tell you how much it helps. The individual trials report symptom scores for single ingredients at other doses. Those numbers are not this product's.
Nobody can tell you how long it takes. No onset time appears on the bottle, in the pack, or in any source we opened. The trials ran five weeks, six weeks and six to twelve months respectively.
Nobody can tell you it repairs a nerve. The brand name says Recovery. The trials measured how people said they felt, not whether anything regenerated.
And nobody can tell you it works for your kind of neuropathy unless yours is diabetic. The research cited on this site is almost entirely in diabetic peripheral neuropathy. Chemotherapy-induced, compressive and B12-deficiency neuropathies are different problems, and the evidence does not transfer.
No published human trial exists on this combination, and none is claimed, so there is no evidence that answers the question directly. What can be checked is each ingredient against the dose its own trials used, and we have done that for all ten. Two land on or near a studied dose, three are full or near-full Daily Values, three have no comparison we would publish, one is a unit error, and one is a thirtieth of the threshold its review names. That is the honest state of it.
It is two-thirds of the dose the main trial recommends. SYDNEY 2 gave 181 patients 600, 1,200 or 1,800 mg once daily for five weeks and concluded that “an oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio.” 400 is not 600. It is the same order of magnitude, which is more than most labels in this category manage, and the trial does not tell us what two-thirds of a dose does.
It is exactly the monotherapy dose from the trial we opened. That study describes its monotherapy arm as “3 x 1 tablets/day, = 150 mg benfotiamine/day.” This label prints 150 mg. To the milligram, it is the studied figure — which is the single most unusual thing on this panel.
No, and the review says so without being asked. Its wording is: “any effect may be present at doses greater than 1500 mg/day but not at lower doses.” 50 mg is one-thirtieth of the smallest figure in that sentence. This is not a marginal shortfall — the threshold is named by the review and the label prints a thirtieth of it.
Four things. Every one of the ten ingredients carries a printed amount — no proprietary blend anywhere, which is the best panel this desk has read. Benfotiamine at 150 mg is the trial's monotherapy dose, to the milligram. The three front-panel claims each carry a dagger that resolves to the FDA disclaimer, which is the correct construction and most packs get it wrong. And the capsule shell is named as hypromellose, so a vegetarian buyer does not have to guess.
Because it is the mean of ten criteria we publish in full. The panel scores 5 out of 5 on its own row and the dose honesty scores 3.5, both the highest this desk has given. Against that: acetyl L-carnitine at a thirtieth of its own review's threshold, three powders with no comparison, a vitamin line that cannot be right, a circulation claim nothing supports, no manufacturer named anywhere on the pack, and no certificate of analysis behind the lot reference we were given.
Two capsules a day and sixty to a bottle, so each bottle lasts thirty days. The brand’s seal shows a 180-day money-back guarantee; read the price and the refund terms on the checkout screen before you pay.
No struck-through “was” price is published for this product, and that is a point in its favour. Where a sales page shows a price crossed out beside a lower one, the crossed-out number is a claim about what the product used to sell for — a claim almost nobody can verify and almost nobody checks. There is nothing of that kind here. · window runs from purchase · no subscription · not for under 18, pregnancy or nursingWritten and fact-checked by The Nerverecovery-max Editorial Desk, last updated October 11, 2026. A highlighted slot means that value has not been supplied yet and nothing has been invented in its place — why the reviewer line is empty.
